Stock Events

Stock Events

Kiora Pharmaceuticals 

$2.55
55
-$0.04-1.54% 18:36 Today

Statistics

Day High
2.68
Day Low
2.52
52W High
2.95
52W Low
1.765
Volume
26,126
Avg. Volume
23,861
Mkt Cap
11.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.81
-0.54
-0.26
0.01
Expected EPS
-0.38
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-10.84MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KPRX. It's not an investment recommendation.
Ford Motor
4
F
Momentus
3
MNTS
Cardio Diagnostics
3
CDIO
Freight Technologies
3
FRGT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals competes in the development of treatments for eye diseases, directly competing with Kiora's focus on ophthalmic diseases.
Novavax
NVAX
Mkt Cap1.33B
Novavax, while primarily known for vaccines, is expanding into therapeutic areas that could overlap with Kiora's research interests.
Bausch Health Companies
BHC
Mkt Cap2.43B
Bausch Health Companies, through its eye health division, competes in the same ophthalmic market as Kiora Pharmaceuticals.
Biogen
BIIB
Mkt Cap31B
Biogen's expansion into therapies for neurological conditions includes research into diseases that can affect vision, overlapping with Kiora's interests.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie, through its acquisition of Allergan, has a strong presence in the ophthalmology sector, competing with Kiora Pharmaceuticals.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a diverse portfolio that includes treatments for conditions potentially overlapping with Kiora's focus areas.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceuticals and medical devices divisions, competes in various healthcare sectors, including eye health.
Novartis
NVS
Mkt Cap286.78B
Novartis has a significant ophthalmology division, directly competing with Kiora Pharmaceuticals in developing treatments for eye diseases.

About

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Show more...
CEO
Brian Strem
Employees
13
Country
United States
ISIN
US49721T5074
WKN
000A40EG5

Listings

STU
DE
7EY.STU
BOATS
BOATS
KPRX.BOATS
MU
DE
7EY.MU
F
DE
7EY.F

0 Comments

Share your thoughts

FAQ

What is Kiora Pharmaceuticals stock price today?▼
The current price of KPRX is $2.55 USD — it has decreased by -1.54% in the past 24 hours. Watch Kiora Pharmaceuticals stock price performance more closely on the chart.
What is Kiora Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Kiora Pharmaceuticals stocks are traded under the ticker KPRX.
Is Kiora Pharmaceuticals stock price growing?▼
KPRX stock has fallen by -3.03% compared to the previous week, the month change is a -2.66% fall, over the last year Kiora Pharmaceuticals has showed a -4.12% decrease.
What is Kiora Pharmaceuticals market cap?▼
Today Kiora Pharmaceuticals has the market capitalization of 11.28M
When is the next Kiora Pharmaceuticals earnings date?▼
Kiora Pharmaceuticals is going to release the next earnings report on November 06, 2026.
What were Kiora Pharmaceuticals earnings last quarter?▼
KPRX earnings for the last quarter are -0.34 USD per share, whereas the estimation was -0.47 USD resulting in a +27.66% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kiora Pharmaceuticals revenue for the last year?▼
Kiora Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Kiora Pharmaceuticals net income for the last year?▼
KPRX net income for the last year is -10.84M USD.
How many employees does Kiora Pharmaceuticals have?▼
As of August 19, 2026, the company has 13 employees.
In which sector is Kiora Pharmaceuticals located?▼
Kiora Pharmaceuticals operates in the Health & Wellness sector.
When did Kiora Pharmaceuticals complete a stock split?▼
The last stock split for Kiora Pharmaceuticals was on June 11, 2024 with a ratio of 1:9.
Where is Kiora Pharmaceuticals headquartered?▼
Kiora Pharmaceuticals is headquartered in ENCINITAS, United States.